- Home
- DMRC vs GALT Comparison
DMRC vs GALT Comparison
Compare DMRC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMRC
- GALT
- Stock Information
- Founded
- DMRC 2008
- GALT 2000
- Country
- DMRC United States
- GALT United States
- Employees
- DMRC N/A
- GALT N/A
- Industry
- DMRC EDP Services
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- DMRC Technology
- GALT Health Care
- Exchange
- DMRC Nasdaq
- GALT Nasdaq
- Market Cap
- DMRC 219.0M
- GALT 232.3M
- IPO Year
- DMRC N/A
- GALT N/A
- Fundamental
- Price
- DMRC $10.14
- GALT $5.34
- Analyst Decision
- DMRC Strong Buy
- GALT Strong Buy
- Analyst Count
- DMRC 1
- GALT 3
- Target Price
- DMRC $30.00
- GALT $6.00
- AVG Volume (30 Days)
- DMRC 159.7K
- GALT 259.7K
- Earning Date
- DMRC 10-30-2025
- GALT 11-12-2025
- Dividend Yield
- DMRC N/A
- GALT N/A
- EPS Growth
- DMRC N/A
- GALT N/A
- EPS
- DMRC N/A
- GALT N/A
- Revenue
- DMRC $35,479,000.00
- GALT N/A
- Revenue This Year
- DMRC N/A
- GALT N/A
- Revenue Next Year
- DMRC N/A
- GALT N/A
- P/E Ratio
- DMRC N/A
- GALT N/A
- Revenue Growth
- DMRC N/A
- GALT N/A
- 52 Week Low
- DMRC $7.77
- GALT $0.73
- 52 Week High
- DMRC $48.32
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- DMRC 56.37
- GALT 63.68
- Support Level
- DMRC $9.19
- GALT $4.77
- Resistance Level
- DMRC $10.43
- GALT $5.36
- Average True Range (ATR)
- DMRC 0.60
- GALT 0.27
- MACD
- DMRC 0.15
- GALT 0.02
- Stochastic Oscillator
- DMRC 87.95
- GALT 98.04
About DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.